. . . "# Thompson PA, Berg SL, Aleksic A, Kerr JZ, McGuffey L, Dauser R, Nuchtern JG, Hausheer F, Blaney SM: Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jun;53(6):527-32. Epub 2004 Mar 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14997342 # Yin MB, Guo B, Vanhoefer U, Azrak RG, Minderman H, Frank C, Wrzosek C, Slocum HK, Rustum YM: Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol. 2000 Mar;57(3):453-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10692484 # Van Hattum AH, Pinedo HM, Schluper HM, Hausheer FH, Boven E: New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer. 2000 Oct 15;88(2):260-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11004678"@en . . . . . . . . . . "Investigated for use/treatment in brain cancer, lung cancer, and melanoma."@en . "BNP 1350"@en . . . "BNP1350 is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer."@en . . . . . . . . . "Karenitecin"@en . . . . "BNP1350, 7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, is a novel semi-synthetic, highly lipophilic, silicon-containing camptothecin and an inhibitor of topoisomerase I. It has been supercomputer engineered for superior oral bioavailability, superior lactone stability, broad anti-tumor activity, increased potency and insensitivity to Pgp/MRP/LRP drug resistance."@en . . . "investigational"@en . . . . . .